European Leukemia Net: Information Letter of the European LeukemiaNet - leukemia, leukaemia, ... Created by: Ihrig (ELIC) , generated 2006/02/14, last changed: 2014/02/03 The Information Letter is provided once per year before the annual Symposium of the European LeukemiaNet. It is a collaboration of the European Leukemia Information Center (ELIC), the Network Management Center (NMC), and the contributing authors.
Topics of this online-publication medium range from basic research to clinical trials and the latest activities of the different work packages. Current issue of the ELN Information Letter WP11 – CYTOGENETICS: Current and future activities in CytogeneticsWP5 – AML: The importance of minimal residual disease (MRD) in AMLWP14 - SCT: Role of stem cell transplantation in elderly patients with AMLWP8 – MDS: Diagnosis and treatment of primary myelodysplastic syndromes in adults. Privious issues of the ELN Information Letter Information Letter no. 9 Information Letter no. 8 Information Letter no. 7 Information Letter no. 6 Editorial-Board Marie C.
InformationLetter_07_2011_web_final. Rundbrief Nr. 7. European Leukemia Net: Network Info - leukemia, leukaemia, ... The American Society of Hematology.
-- SFH -- Sociéte Française d'hématologie. Leucémie myéloïde chronique. Un article de Wikipédia, l'encyclopédie libre. La leucémie myéloïde chronique (LMC) est une prolifération myéloïde monoclonale sans blocage de maturation prédominant sur la lignée granuleuse au niveau médullaire et splénique. Elle fait partie des 4 grands syndromes myéloprolifératifs : Cette maladie touche surtout l'adulte entre 30 et 50 ans et est favorisée par l'exposition au benzène et aux rayons ionisants. C'est l'une des leucémies les plus rares avec par ordre de fréquence : Leucémie lymphoïde chronique → leucémie aiguë → leucémie myéloïde chronique → leucémie à tricholeucocytes. Symptômes cliniques[modifier | modifier le code] Le début est insidieux et certains cas sont découverts fortuitement lors d'un hémogramme de routine chez des sujets apparemment bien portants.
Symptômes généraux[modifier | modifier le code] L'état général est bien conservé au début. Symptômes en rapport avec l'anomalie sanguine[modifier | modifier le code] Cytogénétique et étiologie[modifier | modifier le code] Filmc. Docmglmc20p220610. Filmc. Imatinib may be safely discontinued in patients with CML in remission | HemOncToday: Hematology & Oncology News. Nearly 40% of patients with chronic myeloid leukemia remained in complete molecular remission after discontinuation of imatinib, according to recent study results. Researchers gathered data from 100 patients at 19 participating institutions in France between July 9 and Dec. 17, 2009. The prospective, non-randomized study aimed to determine whether discontinuation of imatinib would lead to molecular relapse in patients in complete molecular remission — defined as a more than 5-log reduction in BCR-ABL and ABL levels and undetectable transcripts on quantitative real-time polymerase chain reaction — while taking the drug.
Eligible patients were 18 years or older and had been taking imatinib for more than 2 years. Patients with at least 12 months of follow-up were evaluated for rate of relapse using real-time polymerase chain reaction. Relapse occurred in 42 (61%) of the 69 patients with at least 12 months of follow-up. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial : The Lancet Oncology. Filmc. Leukemia Foundations - Chronic Myeloid Leukemia.